| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
29,282 |
25,705 |
$1.90M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,832 |
14,111 |
$1.21M |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
3,966 |
772 |
$740K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,425 |
6,197 |
$727K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,594 |
5,079 |
$611K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,623 |
4,455 |
$494K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,551 |
13,861 |
$303K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,524 |
2,426 |
$277K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
9,242 |
8,867 |
$245K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
1,151 |
1,068 |
$239K |
| 90461 |
|
7,692 |
7,090 |
$154K |
| 99401 |
|
9,426 |
8,855 |
$116K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
5,107 |
4,803 |
$107K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
979 |
941 |
$101K |
| 90670 |
|
3,550 |
3,344 |
$100K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,266 |
1,217 |
$99K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,417 |
5,138 |
$79K |
| 99381 |
|
853 |
725 |
$73K |
| 99406 |
|
9,044 |
8,635 |
$66K |
| 90698 |
|
3,902 |
3,715 |
$39K |
| 99383 |
|
287 |
282 |
$33K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,174 |
3,958 |
$28K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
440 |
436 |
$25K |
| 99384 |
|
175 |
171 |
$24K |
| 99188 |
|
2,395 |
2,294 |
$24K |
| 90680 |
|
2,673 |
2,526 |
$18K |
| 85018 |
|
13,026 |
12,562 |
$18K |
| 99382 |
|
139 |
130 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
394 |
389 |
$16K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
843 |
655 |
$12K |
| 99205 |
Prolong outpt/office vis |
92 |
86 |
$10K |
| 90716 |
|
787 |
720 |
$10K |
| 83655 |
|
1,784 |
1,696 |
$10K |
| T2023 |
Targeted case management; per month |
46 |
36 |
$9K |
| 90710 |
|
624 |
594 |
$8K |
| 81002 |
|
5,391 |
5,087 |
$8K |
| 97802 |
|
1,612 |
1,394 |
$7K |
| 90651 |
|
1,368 |
1,331 |
$7K |
| 87807 |
|
811 |
770 |
$7K |
| 90744 |
|
2,275 |
2,161 |
$6K |
| 90707 |
|
743 |
691 |
$6K |
| 92551 |
|
11,928 |
10,375 |
$5K |
| 90633 |
|
2,555 |
2,405 |
$5K |
| 99173 |
|
11,216 |
9,712 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
580 |
552 |
$4K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,536 |
1,385 |
$4K |
| 96127 |
|
2,551 |
2,271 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
118 |
117 |
$2K |
| 0071A |
|
116 |
107 |
$2K |
| 90686 |
|
1,465 |
1,414 |
$2K |
| 90700 |
|
272 |
253 |
$1K |
| 0072A |
|
91 |
89 |
$1K |
| 90671 |
|
416 |
397 |
$1K |
| 90620 |
|
291 |
286 |
$1K |
| 90677 |
|
165 |
159 |
$1K |
| 69210 |
|
173 |
144 |
$981.50 |
| 90734 |
|
493 |
476 |
$829.89 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
37 |
17 |
$796.45 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
130 |
123 |
$747.06 |
| 99051 |
|
89 |
87 |
$586.82 |
| 99402 |
|
50 |
38 |
$433.81 |
| 90713 |
|
26 |
24 |
$429.44 |
| 81001 |
|
44 |
44 |
$415.08 |
| 96161 |
|
414 |
351 |
$410.87 |
| 90696 |
|
618 |
585 |
$364.23 |
| 36416 |
|
10,571 |
9,481 |
$296.74 |
| 0002A |
|
12 |
12 |
$270.00 |
| 0001A |
|
12 |
12 |
$266.00 |
| 90715 |
|
428 |
422 |
$261.49 |
| 90648 |
|
53 |
52 |
$235.89 |
| 90619 |
|
245 |
244 |
$210.00 |
| 90621 |
|
27 |
26 |
$201.81 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
424 |
385 |
$136.33 |
| 90688 |
|
306 |
239 |
$120.27 |
| 99408 |
|
76 |
76 |
$115.71 |
| 99072 |
|
79 |
62 |
$2.90 |
| 91307 |
|
207 |
176 |
$0.23 |
| 91300 |
|
38 |
30 |
$0.01 |
| 99404 |
|
61 |
61 |
$0.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
30 |
26 |
$0.00 |
| 3008F |
|
14 |
12 |
$0.00 |